Stankovikj, Svetlana
Preferred name
Stankovikj, Svetlana
Official Name
Stankovikj, Svetlana
Main Affiliation
Email
svetlana.stankovikj@medf.ukim.edu.mk
106 results
Now showing 1 - 10 of 106
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, non-interventional study(Elsevier Science Direct, 2018-10) ;Mohamed Mohty ;Evangelos Terpos ;Maria-Victoria Mateos ;Michele CavoSandra Lejniece - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Улогата на проточно цитометриската имунофенотипизација во дијагнозата и следењето на акутните леукемии во детска возраст(Лекарска комора на Македонија, 2014); ;Conevska-Jovanova Biljana; ;Acevska-Jovanovska Aleksandra - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Efficasy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (Voncento) in subjects with hemophilia A (SWIFT-HA study)(Elsevier Science Direct, 2016) ;Aleksander Skotnicki ;Toshko J.Lissitckov ;Vasily Mamonov ;Evgeny BuevichKazimerz Kuliczkowski - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Duration of Anticoagulation Therapy in Patients with Genetic Inherited Thrombophilia(Walter de Gruyter GmbH / Macedonian Academy of Sciences and Arts, 2022-07-13) ;Bojovski, Ivica; ; Background: Genetic factors play an important role in deep vein thrombosis (DVT). The duration of anticoagulation therapy in patients with verified genetic inheritance and previous events of DVT is still questionable. Case reports: We present three cases of siblings (two brothers and one sister) with verified Venous thromboembolism (VTE) and genetic inheritance. The first case is a 33 y.o. male who was admitted with bilateral massive pulmonary thromboembolism and DVT of the right femoral vein. He had an episode of DVT 4 years ago. Fibrinolytic therapy was introduced immediately. Afterwards, unfractionated heparin was introduced, and then switched to enoxaparin and acenocoumarol. Because of inappropriate INR, it was switched then to rivaroxaban. The imaging methods showed significant improvement, and the patient was discharged from the hospital with rivaroxaban at 2x15 mg/day for another 2 weeks and was instructed to continue 20 mg/day until his next control. In the meantime, the second case, a 36 y.o. male, brother to the first patient, came with vein thrombosis of vena saphena magna of the left leg. Treatment with Acenocoumarol was started and continued for 2 years until complete resolution of the thrombi, and then it was changed to Aspirin. The third case is the sister of the first 2 cases, a 38 y.o female with symptoms and findings almost similar to those in the second case. She was treated with Acenocoumarol for 6 months. Doppler ultrasound showed complete resolution of the thrombosis and anticoagulation therapy was stopped. Genetic investigations for mutation showed presence of homozygous gene mutation for Prothrombin (PTB G20210A) in the first patient, his brother (the second case) was compound heterozygote for PTB and for MTHFR C677T, and his sister (third case) was heterozygous only for the PTB mutation. According to the clinical (recurrent unprovoked DVT with thromboembolic complications) and genetic testing (homozygous gene mutation for PTB) in the first patient, we decided to continue the secondary thromboprophylaxis with rivaroxaban 10 mg/day indefinitely. Conclusion: Testing for genetically inherited thrombophilia should be included in the risk assessment for recurrence, and performed in all patients under 50 y.o. who have a first, non-provoked episode of thrombosis, in order to determine the duration of anticoagulation therapy. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Sex-related differences regarding cephalic vein lead access for CIEDs implantation(Springer Science and Business Media LLC, 2021-11-17); ; ;Risteski, Dejan ;Janusevski, FilipPocesta, Bekim<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Minimally invasive and safe central venous access is imperative for lead insertion of cardiac implantable electronic devices (CIEDs). The purpose of this trial was to explore and compare the usability of the cephalic vein (CV) between both sexes.</jats:p> </jats:sec><jats:sec> <jats:title>Methods and results</jats:title> <jats:p>This single-center prospective study included 102 consecutive patients in a period of six months. Pre-procedural contrast-enhanced venographic images of the upper arm were performed in all included patients. Our attention was focused on comparing several morpho-anatomical CV characteristics such as venous diameter, presence of valves and angle of entrance of the CV into the subclavian vein (SV). Study results concerning the CV morpho-anatomical differences were more favorable regarding the female patient group, with significant differences in CV diameter (<jats:italic>p</jats:italic>-0.030). There was also a difference in favor of the female group regarding the favorable CV angle of entrance into the SV, found in the 61.7% versus 54.4% in the male patient group. The comparison of usability of the CV and CVC technique was explored by comparing the number of leads inserted through the CV in both sexes. Two leads were implanted in 11.7% in the female group versus 5.8% in the male group, and 0 leads through the CV in 38.2% of the female patients versus 50% of male group.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Female patients have more favorable cephalic vein morpho-anatomical futures and better usability for lead placement than male patients.</jats:p> </jats:sec> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Акривирана хемофилија - ретка но потенцијално живото-загрозувачка состојба за двата пола(Лекарска комора на Македонија, 2015-03); ;Smilevska Tatjana; Cevreska Lidija - Some of the metrics are blocked by yourconsent settings
Item type:Publication, CLL-132: Mutational Status of IGVH in Correlation with Genetic Abnormalities of Patients with Chronic Lymphocytic Leukemia in Macedonia - A Single-Centre Experience(Elsevier BV, 2020-09); ; ;Popova-Labacevska, Marija; Ivanovski, Martin - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prognostic model for stratification of patients with chronic lymphocytic leukemia(Association of the Albanian Doctors from Macedonia, 2013-09); ;Cevreska, Lidija ;Ivanovski, Martin ;Dukovski, DuskoSimjanovska Popova, Marija - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Improved survival in patients with TTP (Sy Moskowitz)(Medical Faculty, Ss. Cyril and Methodius University in Skopje, 2016); ; Stankovic Vera - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Case report of a rare coagulation disorder-Acquired hemophilia A(Medical Faculty, Ss. Cyril and Methodius University in Skopje, 2016); ; ;Ivanovski Martin;
